Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In immunotherapy, the patients´ immune system is activated to cure cancer. The term tumor-directed means that the drug is administered or designed such that the pharmacological effect is localized to the tumor. This results in an advantageous efficacy and safety profile.
The company is primarily active in the early phases of drug development, from the idea stage to clinical phase II trials. This includes identification of innovative modes of action for pharmaceuticals, producing and optimizing new drug candidates, evaluation of preclinical efficacy and safety, and finally confirmatory clinical studies in cancer patients.
Alligator was founded in 2001 and is located at Medicon Village in Lund, Sweden.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.